|Bid||29.91 x 900|
|Ask||29.95 x 1100|
|Day's Range||29.84 - 30.60|
|52 Week Range||29.01 - 64.37|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||54.94|
Subscribe to Yahoo Finance Plus to view Fair Value for IONSLearn more
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 873 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Shares of Ionis Pharmaceuticals (NASDAQ: IONS), a biotechnology company, have fallen around 13.6% since their closing price on Friday, Oct. 15, 2021. Investors were disappointed by phase 3 clinical trial results for tofersen, an experimental treatment for amyotrophic lateral sclerosis. Treatment with tofersen was supposed to help reduce physical symptoms of ALS, a progressive neurodegenerative disorder that affects around 20,000 new U.S. patients annually.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 3rd at 11:30 a.m. Eastern Time to discuss its third quarter 2021 financial results and report on pipeline and business progress.